CRVO

Companies
NASDAQ
Cervomed Inc.
Health Care
Price Chart
Overview

About CRVO

CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

Market Cap
$158.4M
Volume
1.5M
Avg. Volume
2.7M
P/E Ratio
-3.456693
Dividend Yield
0.00%
Employees
13.0

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Biotechnology
Risk & Correlation Analysis
Market Correlation
0.53
Low Correlation
Volatility
High (1.00)
Relative to market

Macro Factor Sensitivities

Interest Rates
Low Sensitivity
Inflation
High Sensitivity
GDP Growth
High Sensitivity
Liquidity
High Sensitivity
Commodity Prices
High Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for CRVO.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, CRVO shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$158.4M
Volume1.5M
P/E Ratio-3.46
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 12, 2025
Related Securities

PortfolioPilot Analysis

Get AI-powered insights on how CRVO fits into your investment strategy and portfolio diversification.

Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025